Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1820390 | 0.88 | MEN1 (0.51) | KDM1AMEN1KMT2ASIGMAR1 | |
| SCHEMBL12390025 | 0.82 | MEN1 (0.49) | KDM1AMAOBMEN1KMT2ASIGMAR1 | |
| SCHEMBL22202531 | 0.80 | SIGMAR1 (0.37) | MEN1KMT2ASIGMAR1HTR2A | |
| SCHEMBL10735132 | 0.79 | MEN1 (0.42) | KDM1AMAOBMEN1KMT2ASIGMAR1 | |
| SCHEMBL2592743 | 0.78 | HTR2A (0.36) | MEN1KMT2ASIGMAR1HTR2A | |
| SCHEMBL2468439 | 0.76 | KDM1A (0.46) | KDM1AMAOBMEN1KMT2ASIGMAR1 | |
| SCHEMBL388323 | 0.76 | KDM1A (0.42) | KDM1AMAOBMEN1KMT2ASIGMAR1 | |
| SCHEMBL412891 | 0.76 | KDM1A (0.48) | KDM1AMAOBMEN1KMT2ATSHR | |
| SCHEMBL29529565 | 0.76 | KDM1A (0.48) | KDM1AMAOBMEN1KMT2ATSHR | |
| SCHEMBL6451307 | 0.75 | KDM1A (0.41) | KDM1AMAOBMEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-10-07 | — | — | US | disclosed |
| EP-2875362-A1 | TEST KIT FOR THE QUANTITATIVE DETERMINATION OF NARCOTIC DRUGS | Chiron AS (NO) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014013063-A1 | TEST KIT FOR THE QUANTITATIVE DETERMINATION OF NARCOTIC DRUGS | CHIRON AS (NO) | 2014-01-23 | — | — | WO | disclosed |
| CN-101772487-B | Thyroid compounds | TORRENT PHARMACEUTICALS LTD | 2014-01-22 | — | — | CN | disclosed |
| CN-101772487-A | Novel compound | TORRENT PHARMACEUTICALS LTD | 2010-07-07 | — | — | CN | disclosed |
| CN-101128421-A | Methods and compositions for treating amyloid-related diseases | NEUROCHEM INTERNAT LTD (CH) | 2008-02-20 | — | — | CN | disclosed |
| CN-1166622-C | 2-amino-1, 2-indanes as selective dopamine D3 ligands | �������Ŷ���Լ��������˾ | 2004-09-15 | — | — | CN | disclosed |
| CN-1172469-A | 2 -aminoindans as selective dopamine D3 ligands | UPJOHN CO (US) | 1998-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | VHL, MDM2, CUL2 | KDM1A 1991/4885MAOB 4192/4885MEN1 2547/4885 |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | VHL, MDM2, CUL2 | KDM1A 1991/4885MAOB 4192/4885MEN1 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.